Here are my takeaways for the 7 most relevant and important #ESCCongress2025 for generalists AQUATIC, HI-PRO, RETREAT-FRAIL, DIGIT-HF, DAN-RSV were most practicing changing POTCAST was most contentious - not as billed

🙏Incredibly grateful to @almallahmo for supervision , @MalekNayfeh, Fares AlAhdab, Mahmoud Al Rifai, @DmitryAbramovMD, @FudimMarat , @YasMoayedi, @RayanYousefzai for their incredible support, and to @JACCJournals CV imaging for the opportunity to publish our work🙏

Do heart transplant patients always need invasive angio to screen for graft vasculopathy❓ 📜 https://t.co/JVR5PRa1VN In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.

NEW PAPER in @bmj_latest "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide" --> https://t.co/4YGRasQVrx #methodologymatters

Over the past 41 years, death due to ischemic heart disease did not decline in countries with low socioeconomic development, research shows @ASayedMD @MethodistHosp @virani_md @ErinMichos @annmarienavar @DrLaPrincess https://t.co/mDlDtJTqov

🙏🙏Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ 🙏🙏 And thank you to @EHJCVIEiC for allowing us to share our findings!

Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow. In contrast, patients with a depressed EF had a uniformly high rate of events regardless.

Our hypothesis was that an elevated amount of myocardial blood flow at rest, which PET can measure, would predict adverse event rates. And it did, esp. in patients with a normal EF at rest.

First, some background. Prior data indicated that the myocardium of patients with LVH/HFpEF receives an excessive amount of blood flow at rest ( https://t.co/wMmWdtnvF9) There is also mechanistic data that medications effective in HFpEF reduce this ( https://t.co/QIbXSAlPzu)

1/4🧵 In patients undergoing cardiac stress testing w/ PET, does rest flow matter❓ In an analysis of >8k patients, we find that it does, esp. in patients with a preserved EF. Link📜: https://t.co/05Nxx0K95o @almallahmo @MariaAlwan_ @MyASNC @MethodistHosp @EHJCVIEiC

𝐃𝐒𝐄 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐬 𝐢𝐧 𝐎𝐑𝐁𝐈𝐓𝐀-𝟐: Stress echo ischemia identifies who 𝘳𝘦𝘢𝘭𝘭𝘺 benefits from PCI. 📖 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐢𝐧 #𝐉𝐀𝐂𝐂: https://t.co/SoNkeJ0zVW @rallamee @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai

An incredible experience at #DDW2025! Privileged to share our work on #pancreaticcancer, Fatty Pancreas, and #colorectalcancer With 3 oral presentations, and 3 poster presentations ✅ Immensely grateful for the mentorship and support of Dr. @SriGaddamMD 🙏🏼

New genetic analysis in 200k people over 14 years ▶️apoB + lp(a) best capture lipid-mediated CV risk ▶️LDL particle size adds no additional info when apoB is accounted for https://t.co/Kv7sUxAcmv

Intensive LDL-C lowering with Evolocumab may lead to greater relative reduction in cardiovascular events in patients with autoimmune or inflammatory diseases. @AndreZimerman @bweber04 @analaurakunzler @rgiuglaino https://t.co/oYtX8Vbxqu

Just in time for #HRS2025‼️ Excited to share our latest paper published in @AmericanHeartJ and honored to be first co-author with Dr. Bockus. Looking forward to presenting our work in San Diego. https://t.co/n3AsBU4bNw @NazemAkoum @UWMedHeart

We have an opening for an advanced imaging fellowship position available starting July 2025 at @MonteHeart. Applicants that have completed cardiology training are preferred. International applicants with USMLE certification will be considered. @aschenonegiugni @CarlosGongoraMD

PET-derived global MFR is inversely associated with subsequent cardiovascular outcomes in all BMI categories @almallahmo @HMethodistMD @HMethodistCV Read now👉 https://t.co/748cbVedLw #cvnuc

Read our latest work in @CircIntv led by Dr Zmaili and supervised by Dr @tavrkapadia

🧵Renal Denervation (RDN) for Hypertension – A meta-analysis of 12 sham-controlled RCTs in @ehjopen https://t.co/d1G916H0Xi @jennifer_rymer @RVSwaminathanMD @manesh_patelMD @FudimMarat

🙏Immensely grateful to Drs. @MartinMaronMD @EthanRowin and Dr. Barry Maron for their guidance and mentorship on this work🙏